Loading...

We've got a brand new version of Simply Wall St! Try it out

eSense-Lab

ASX:ESE
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ESE
ASX
A$2M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

eSense-Lab Limited, a life sciences research and development company, specializes in the commercialization of phytochemical profiling of plants. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • eSense-Lab has significant price volatility in the past 3 months.
ESE Share Price and Events
7 Day Returns
9.1%
ASX:ESE
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-73.3%
ASX:ESE
50.9%
AU Biotechs
16.3%
AU Market
ESE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
eSense-Lab (ESE) 9.1% -33.3% -47.8% -73.3% - -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • ESE underperformed the Biotechs industry which returned 50.9% over the past year.
  • ESE underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
ESE
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for eSense-Lab's competitors could be found in our database.

ESE Value

 Is eSense-Lab undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for eSense-Lab. This is due to cash flow or dividend data being unavailable. The share price is A$0.012.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for eSense-Lab's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are eSense-Lab's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ESE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.01
ASX:ESE Share Price ** ASX (2019-11-15) in AUD A$0.01
ASX:ESE Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.681 $0.01
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of eSense-Lab.

ASX:ESE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ESE Share Price ÷ EPS (both in USD)

= 0.01 ÷ -0.01

-0.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • eSense-Lab is loss making, we can't compare its value to the Global Biotechs industry average.
  • eSense-Lab is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does eSense-Lab's expected growth come at a high price?
Raw Data
ASX:ESE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for eSense-Lab, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on eSense-Lab's assets?
Raw Data
ASX:ESE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.01
ASX:ESE Share Price * ASX (2019-11-15) in AUD A$0.01
ASX:ESE Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.681 $0.01
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:ESE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ESE Share Price ÷ Book Value per Share (both in USD)

= 0.01 ÷ 0.01

1.39x

* Primary Listing of eSense-Lab.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • eSense-Lab is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess eSense-Lab's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. eSense-Lab has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ESE Future Performance

 How is eSense-Lab expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as eSense-Lab has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is eSense-Lab expected to grow at an attractive rate?
  • Unable to compare eSense-Lab's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare eSense-Lab's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare eSense-Lab's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:ESE Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ESE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ESE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ASX:ESE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -2 -2
2019-03-31 0 -2 -2
2018-12-31 0 -2 -2
2018-09-30 0 -2 -2
2018-06-30 0 -2 -2
2018-03-31 0 -2 -2
2017-12-31 0 -2 -2
2017-09-30 0 -2 -6
2016-12-31 0 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if eSense-Lab is high growth as no earnings estimate data is available.
  • Unable to determine if eSense-Lab is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ESE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from eSense-Lab Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ESE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ASX:ESE Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.01
2019-03-31 -0.02
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.03
2017-12-31 -0.04
2017-09-30 -0.09
2016-12-31 -0.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if eSense-Lab will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine eSense-Lab's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. eSense-Lab's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. eSense-Lab's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess eSense-Lab's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
eSense-Lab has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ESE Past Performance

  How has eSense-Lab performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare eSense-Lab's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • eSense-Lab does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare eSense-Lab's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare eSense-Lab's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
eSense-Lab's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from eSense-Lab Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ESE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.02 -1.73 1.62 0.25
2019-03-31 0.02 -1.96 1.71 0.31
2018-12-31 0.03 -2.20 1.79 0.36
2018-09-30 0.03 -2.13 1.80 0.32
2018-06-30 0.04 -2.06 1.81 0.27
2018-03-31 0.06 -2.08 1.79 0.28
2017-12-31 0.08 -2.11 1.77 0.29
2017-09-30 0.07 -6.32 4.91 0.43
2016-12-31 -4.87 3.62 0.34

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if eSense-Lab has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if eSense-Lab has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if eSense-Lab improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess eSense-Lab's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
eSense-Lab has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ESE Health

 How is eSense-Lab's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up eSense-Lab's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • eSense-Lab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • eSense-Lab's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of eSense-Lab's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • eSense-Lab has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from eSense-Lab Company Filings, last reported 4 months ago.

ASX:ESE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1.12 0.00 1.25
2019-03-31 1.12 0.00 1.25
2018-12-31 1.64 0.00 1.98
2018-09-30 1.64 0.00 1.98
2018-06-30 1.01 0.00 0.95
2018-03-31 1.01 0.00 0.95
2017-12-31 2.22 0.00 2.43
2017-09-30 2.22 0.00 2.43
2016-12-31 -1.07 1.40 0.48
  • eSense-Lab has no debt.
  • eSense-Lab currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • eSense-Lab has less than a year of cash runway based on current free cash flow.
  • eSense-Lab has less than a year of cash runway if free cash flow continues to grow at historical rates of 30.4% each year.
X
Financial health checks
We assess eSense-Lab's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. eSense-Lab has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ESE Dividends

 What is eSense-Lab's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from eSense-Lab dividends.
If you bought A$2,000 of eSense-Lab shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate eSense-Lab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate eSense-Lab's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ESE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:ESE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as eSense-Lab has not reported any payouts.
  • Unable to verify if eSense-Lab's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of eSense-Lab's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as eSense-Lab has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess eSense-Lab's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can eSense-Lab afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. eSense-Lab has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ESE Management

 What is the CEO of eSense-Lab's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Haim Cohen
COMPENSATION $189,544
TENURE AS CEO 3.2 years
CEO Bio

Mr. Haim Cohen has been the Chief Executive Officer at eSense-Lab Ltd. since November 19, 2016 and served as its Executive Director since October 1, 2016 until February 13, 2019. Mr. Cohen also serves as Managing Director of eSense-Lab Ltd. He has extensive managerial experience across numerous sectors including real estate, transport communications, human resources and information systems in both private and government enterprises. He has a successful track record in business development and marketing and has been a manager of project budgets of up to US$4 billion. He represented the Israeli Government as Chairman of the youth exchange authority in Israel. Mr. Cohen holds a B.A in social science from Bar Ilan University.

CEO Compensation
  • Insufficient data for Haim to compare compensation growth.
  • Insufficient data for Haim to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team

Haim Cohen

TITLE
CEO & MD
COMPENSATION
$190K
TENURE
3.2 yrs

Yaron Penn

TITLE
Chief Technical Officer
COMPENSATION
$160K

Mira Carmeli Weissberg

TITLE
Chief Scientific Officer
COMPENSATION
$118K

Yacob Cohen

TITLE
Chief Financial Officer

Sebastian Andre

TITLE
Company Secretary
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure of the eSense-Lab board of directors in years:

1
Average Tenure
  • The average tenure for the eSense-Lab board of directors is less than 3 years, this suggests a new board.
Board of Directors

Piers Lewis

TITLE
Chairman
TENURE
1 yrs

Benjamin Karasik

TITLE
Non-Executive Director
TENURE
1.8 yrs

Amit Edri

TITLE
Non-Executive Director
TENURE
1 yrs

Mike Edwards

TITLE
Non-Executive Director
AGE
51
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by eSense-Lab individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
24. Oct 19 Buy James Schwarz Individual 02. Sep 19 10. Oct 19 3,810,613 A$0.02 A$69,487
X
Management checks
We assess eSense-Lab's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. eSense-Lab has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ESE News

Simply Wall St News

What Kind Of Investor Owns Most Of eSense-Lab Limited (ASX:ESE)?

A look at the shareholders of eSense-Lab Limited (ASX:ESE) can tell us which group is most powerful. … eSense-Lab is not a large company by global standards. … Let's take a closer look to see what the different types of shareholder can tell us about ESE

Simply Wall St -

What Type Of Shareholder Owns eSense-Lab Limited's (ASX:ESE)?

Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'.

Simply Wall St -

Was eSense-Lab Limited's (ASX:ESE) Earnings Growth Better Than The Industry's?

When eSense-Lab Limited (ASX:ESE) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … See our latest analysis for eSense-Lab Were ESE's earnings stronger than its past performances and the industry? … For eSense-Lab, its most recent earnings (trailing twelve month) is -US$2.11M, which, against last year’s level, has become less negative.

Simply Wall St -

What You Must Know About eSense-Lab Limited's (ASX:ESE) Major Investors

Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … General Public Ownership The general public holds 5.54% stake in ESE, thus, representing an important class of owners. … This size of ownership, while considerably large for a public company, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Simply Wall St -

Breakeven On The Horizon For eSense-Lab Ltd (ASX:ESE)

ASX:ESE Past Future Earnings Mar 30th 18 Given this is a high-level overview, I won’t go into detail the detail of ESE’s upcoming projects, though, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. … Next Steps: This article is not intended to be a comprehensive analysis on ESE, so if you are interested in understanding the company at a deeper level, take a look at ESE’s company page on Simply Wall St. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

Simply Wall St -

Should You Invest In The Healthcare Stock eSense-Lab Ltd (ASX:ESE)?

Unsuprisingly, this is below the growth rate of the Australian stock market as a whole. … In the past year, the industry delivered growth in the teens, beating the Australian market growth of 7.19%. … If eSense-Lab has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

eSense-Lab Ltd (ASX:ESE): Is It Growing Too Fast?

Cash is crucial to run a business, and if a company burns through its reserves fast, it will need to come back to market for additional capital raising. … Cash burn is when a loss-making company spends its equity to fund its expenses before making money from its day-to-day business. … Companies with high cash burn rates can eventually turn into ashes, which makes it the biggest risk an investor in loss-making companies face.

Simply Wall St -

ESE Company Info

Description

eSense-Lab Limited, a life sciences research and development company, specializes in the commercialization of phytochemical profiling of plants. The company focuses on the development and manufacturing of terpene profiles of the cannabis plant for use in various applications, such as concentrates, medicine, topical treatments, e-liquids, beverages, personalized medicine, cosmetics, and food additives. eSense-Lab Limited was incorporated in 2016 and is based in Nes Tziona, Israel.

Details
Name: eSense-Lab Limited
ESE
Exchange: ASX
Founded: 2016
A$2,276,123
189,676,918
Website: http://www.esense-lab.com
Address: eSense-Lab Limited
8 Sapir Street,
Nes Tziona,
7403631,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ESE CDI 1:1 Australian Securities Exchange AU AUD 14. Feb 2017
CHIA ESE CDI 1:1 Chi-X Australia AU AUD 14. Feb 2017
Number of employees
Current staff
Staff numbers
0
eSense-Lab employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:42
End of day share price update: 2019/11/15 00:00
Last estimates confirmation: 2018/02/28
Last earnings filing: 2019/08/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.